Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2405859 | Vaccine | 2008 | 7 Pages |
Abstract
Severe acute respiratory syndrome (SARS) is a serious infectious disease caused by the SARS coronavirus. We assessed the potential of prime-boost vaccination protocols based on the nucleocapsid (NC) protein co-administered with a derivative of the mucosal adjuvant MALP-2 or expressed by modified Vaccinia virus Ankara (MVA–NC) to stimulate humoral and cellular immune responses at systemic and mucosal levels. The obtained results demonstrated that strong immune responses can be elicited both at systemic and mucosal levels following a heterologous prime-boost vaccination protocol consisting in priming with NC protein add-mixed with MALP-2 by intranasal route and boosting with MVA–NC by intramuscular route.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Kai Schulze, Caroline Staib, Hermann M. Schätzl, Thomas Ebensen, Volker Erfle, Carlos A. Guzman,